Effect of docosahexaenoic acid‐enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition—double‐blinded randomized placebo‐controlled trial. Issue 11 (28th June 2014)
- Record Type:
- Journal Article
- Title:
- Effect of docosahexaenoic acid‐enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition—double‐blinded randomized placebo‐controlled trial. Issue 11 (28th June 2014)
- Main Title:
- Effect of docosahexaenoic acid‐enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition—double‐blinded randomized placebo‐controlled trial
- Authors:
- Min, Y.
Djahanbakhch, O.
Hutchinson, J.
Bhullar, A. S.
Raveendran, M.
Hallot, A.
Eram, S.
Namugere, I.
Nateghian, S.
Ghebremeskel, K. - Abstract:
- <abstract abstract-type="main" id="dme12524-abs-0001"> <title>Abstract</title> <sec id="dme12524-sec-0001" sec-type="section"> <title>Aims</title> <p>To test if docosahexaenoic acid‐enriched fish oil supplementation rectifies red cell membrane lipid anomaly in pregnant women with Type 2 diabetes and their neonates, and alters fetal body composition.</p> </sec> <sec id="dme12524-sec-0002" sec-type="section"> <title>Methods</title> <p>Women with Type 2 diabetes (<italic>n</italic> = 88; 41 fish oil, 47 placebo) and healthy women (<italic>n</italic> = 85; 45 fish oil, 40 placebo) were supplemented from the first trimester until delivery. Blood fatty acid composition, fetal biometric and neonatal anthropometric measurements were assessed.</p> </sec> <sec id="dme12524-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 117 women completed the trial. The women with Type 2 diabetes who took fish oil compared with those who received placebo had higher percentage of docosahexaenoic acid in red cell phosphatidylethanolamine in the third trimester (12.0% vs. 8.9%, <italic>P </italic>= 0.000) and at delivery (10.7% vs. 7.4%, <italic>P </italic>= 0.001). Similarly, the neonates of the women with Type 2 diabetes supplemented with the fish oil had increased docosahexaenoic acid in the red cell phosphatidylethanolamine (9.2% vs. 7.7%, <italic>P </italic>= 0.027) and plasma phosphatidylcholine (6.1% vs. 4.7%, <italic>P </italic>= 0.020). Docosahexaenoic acid‐rich fish oil had<abstract abstract-type="main" id="dme12524-abs-0001"> <title>Abstract</title> <sec id="dme12524-sec-0001" sec-type="section"> <title>Aims</title> <p>To test if docosahexaenoic acid‐enriched fish oil supplementation rectifies red cell membrane lipid anomaly in pregnant women with Type 2 diabetes and their neonates, and alters fetal body composition.</p> </sec> <sec id="dme12524-sec-0002" sec-type="section"> <title>Methods</title> <p>Women with Type 2 diabetes (<italic>n</italic> = 88; 41 fish oil, 47 placebo) and healthy women (<italic>n</italic> = 85; 45 fish oil, 40 placebo) were supplemented from the first trimester until delivery. Blood fatty acid composition, fetal biometric and neonatal anthropometric measurements were assessed.</p> </sec> <sec id="dme12524-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 117 women completed the trial. The women with Type 2 diabetes who took fish oil compared with those who received placebo had higher percentage of docosahexaenoic acid in red cell phosphatidylethanolamine in the third trimester (12.0% vs. 8.9%, <italic>P </italic>= 0.000) and at delivery (10.7% vs. 7.4%, <italic>P </italic>= 0.001). Similarly, the neonates of the women with Type 2 diabetes supplemented with the fish oil had increased docosahexaenoic acid in the red cell phosphatidylethanolamine (9.2% vs. 7.7%, <italic>P </italic>= 0.027) and plasma phosphatidylcholine (6.1% vs. 4.7%, <italic>P </italic>= 0.020). Docosahexaenoic acid‐rich fish oil had no effect on the body composition of the fetus and neonates of the women with Type 2 diabetes.</p> </sec> <sec id="dme12524-sec-0004" sec-type="section"> <title>Conclusions</title> <p>A daily dose of 600 mg of docosahexaenoic acid was effective in ameliorating red cell membrane docosahexaenoic acid anomaly in pregnant women with Type 2 diabetes and neonates, and in preventing the decline of maternal docosahexaenoic acid during pregnancy. We suggest that the provision of docosahexaenoic acid supplement should be integrated in the antenatal care of pregnant women with Type 2 diabetes.</p> </sec> </abstract> … (more)
- Is Part Of:
- Diabetic medicine. Volume 31:Issue 11(2014:Nov.)
- Journal:
- Diabetic medicine
- Issue:
- Volume 31:Issue 11(2014:Nov.)
- Issue Display:
- Volume 31, Issue 11 (2014)
- Year:
- 2014
- Volume:
- 31
- Issue:
- 11
- Issue Sort Value:
- 2014-0031-0011-0000
- Page Start:
- 1331
- Page End:
- 1340
- Publication Date:
- 2014-06-28
- Subjects:
- Diabetes -- Periodicals
616.462 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=dme ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/dme.12524 ↗
- Languages:
- English
- ISSNs:
- 0742-3071
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.606000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3291.xml